FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2790654552> ?p ?o ?g. }

• W2790654552 endingPage "1330" @default.
• W2790654552 startingPage "1321" @default.
• W2790654552 abstract "T-type calcium channels have been shown to play an important role in the initiation and maintenance of neuropathic pain and represent a promising therapeutic target for new analgesic treatments. Ethosuximide (ETX), an anticonvulsant and a T-type channel blocker has shown analgesic effect in several chronic pain models but has not yet been evaluated in patients with neuropathic pain.This proof-of-concept, multicentre, double-blind, controlled and randomized trial compared the efficacy and safety of ETX (given as add-on therapy) to an inactive control (IC) in 114 patients with non-diabetic peripheral neuropathic pain. After a 7-day run-in period, eligible patients aged over 18 years were randomly assigned (1:1) to ETX or IC for 6 weeks. The primary outcome was the difference between groups in the pain intensity (% of change from the baseline to end of treatment) assessed in the intention-to-treat population. This study is registered with EudraCT (2013-004801-26) and ClinicalTrials.gov (NCT02100046).The study was stopped during the interim analysis due to the high number of adverse events in the active treatment group. ETX failed to reduce total pain and showed a poor tolerance in comparison to IC. In the per-protocol analysis, ETX significantly reduced pain intensity by 15.6% (95% CI -25.8; -5.4) from baseline compared to IC (-7.8%, 95% CI -14.3; -1.3; p = 0.033), but this result must be interpreted with caution because of a small subgroup of patients.Ethosuximide did not reduce the severity of neuropathic pain and induces, at the doses used, many adverse events.This article shows that ETX is not effective to treat neuropathic pain. Nevertheless, per-protocol analysis suggests a possible analgesic effect of ETX. Thus, our work adds significant knowledge to preclinical and clinical data on the benefits of T-type calcium channel inhibition for the treatment of neuropathic pain." @default.
• W2790654552 created "2018-03-29" @default.
• W2790654552 creator A5004561817 @default.
• W2790654552 creator A5008093301 @default.
• W2790654552 creator A5010795152 @default.
• W2790654552 creator A5012970834 @default.
• W2790654552 creator A5013394355 @default.
• W2790654552 creator A5013540053 @default.
• W2790654552 creator A5014284349 @default.
• W2790654552 creator A5014766042 @default.
• W2790654552 creator A5016623304 @default.
• W2790654552 creator A5017107612 @default.
• W2790654552 creator A5027362941 @default.
• W2790654552 creator A5027849743 @default.
• W2790654552 creator A5033397745 @default.
• W2790654552 creator A5033543494 @default.
• W2790654552 creator A5034429239 @default.
• W2790654552 creator A5038631234 @default.
• W2790654552 creator A5045536261 @default.
• W2790654552 creator A5045576370 @default.
• W2790654552 creator A5047066044 @default.
• W2790654552 creator A5047070422 @default.
• W2790654552 creator A5047739587 @default.
• W2790654552 creator A5048658964 @default.
• W2790654552 creator A5049016800 @default.
• W2790654552 creator A5050068766 @default.
• W2790654552 creator A5053305030 @default.
• W2790654552 creator A5053669249 @default.
• W2790654552 creator A5063697285 @default.
• W2790654552 creator A5071748263 @default.
• W2790654552 creator A5073711627 @default.
• W2790654552 creator A5075478051 @default.
• W2790654552 creator A5076308553 @default.
• W2790654552 creator A5081195880 @default.
• W2790654552 creator A5081910669 @default.
• W2790654552 creator A5082592503 @default.
• W2790654552 creator A5083118435 @default.
• W2790654552 creator A5084509816 @default.
• W2790654552 creator A5085358172 @default.
• W2790654552 creator A5087185601 @default.
• W2790654552 creator A5088211841 @default.
• W2790654552 creator A5088674040 @default.
• W2790654552 creator A5090943328 @default.
• W2790654552 date "2018-04-18" @default.
• W2790654552 modified "2023-10-17" @default.
• W2790654552 title "Efficacy and safety of a T-type calcium channel blocker in patients with neuropathic pain: A proof-of-concept, randomized, double-blind and controlled trial" @default.
• W2790654552 cites W1559837393 @default.
• W2790654552 cites W1815399785 @default.
• W2790654552 cites W1845250825 @default.
• W2790654552 cites W1966892791 @default.
• W2790654552 cites W1975195985 @default.
• W2790654552 cites W1984486655 @default.
• W2790654552 cites W1988364618 @default.
• W2790654552 cites W2020345477 @default.
• W2790654552 cites W2026423509 @default.
• W2790654552 cites W2033748627 @default.
• W2790654552 cites W2039898366 @default.
• W2790654552 cites W2041635174 @default.
• W2790654552 cites W2059306741 @default.
• W2790654552 cites W2070294630 @default.
• W2790654552 cites W2087188787 @default.
• W2790654552 cites W2094267095 @default.
• W2790654552 cites W2104818454 @default.
• W2790654552 cites W2110707035 @default.
• W2790654552 cites W2127894556 @default.
• W2790654552 cites W2136415182 @default.
• W2790654552 cites W2139498473 @default.
• W2790654552 cites W2143017058 @default.
• W2790654552 cites W2143994109 @default.
• W2790654552 cites W2155412494 @default.
• W2790654552 cites W2171830917 @default.
• W2790654552 cites W2172151487 @default.
• W2790654552 cites W2413563664 @default.
• W2790654552 cites W2419648767 @default.
• W2790654552 cites W2561584318 @default.
• W2790654552 cites W2790599495 @default.
• W2790654552 doi "https://doi.org/10.1002/ejp.1221" @default.
• W2790654552 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29577519" @default.
• W2790654552 hasPublicationYear "2018" @default.
• W2790654552 type Work @default.
• W2790654552 sameAs 2790654552 @default.
• W2790654552 citedByCount "20" @default.
• W2790654552 countsByYear W27906545522018 @default.
• W2790654552 countsByYear W27906545522019 @default.
• W2790654552 countsByYear W27906545522020 @default.
• W2790654552 countsByYear W27906545522021 @default.
• W2790654552 countsByYear W27906545522022 @default.
• W2790654552 countsByYear W27906545522023 @default.
• W2790654552 crossrefType "journal-article" @default.
• W2790654552 hasAuthorship W2790654552A5004561817 @default.
• W2790654552 hasAuthorship W2790654552A5008093301 @default.
• W2790654552 hasAuthorship W2790654552A5010795152 @default.
• W2790654552 hasAuthorship W2790654552A5012970834 @default.
• W2790654552 hasAuthorship W2790654552A5013394355 @default.
• W2790654552 hasAuthorship W2790654552A5013540053 @default.
• W2790654552 hasAuthorship W2790654552A5014284349 @default.
• W2790654552 hasAuthorship W2790654552A5014766042 @default.
• W2790654552 hasAuthorship W2790654552A5016623304 @default.

• next